NCT06430684View on ClinicalTrials.gov

Feasibility Trial of Sodium-GLucose CoTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

June 1, 2026

Conditions
Chronic Kidney DiseasesPediatric Kidney Disease
Interventions
DRUG

Empagliflozin 10 MG

Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older

Trial Locations (1)

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER